Compare BTCT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | CALC |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Singapore | United States |
| Employees | 26 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | BTCT | CALC |
|---|---|---|
| Price | $1.21 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 183.1K | ★ 296.5K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | ★ N/A | $2.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $0.46 |
| 52 Week High | $4.47 | $7.20 |
| Indicator | BTCT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 58.19 |
| Support Level | $1.25 | $0.52 |
| Resistance Level | $1.36 | $0.93 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.50 | 50.12 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.